Finding hidden treasures in old drugs: the challenges and importance of licensing generics
This paper was originally published by Melek Simsek, Berrie Meijer, Adriaan A. van Bodegraven, Nanne K.H. de Boer, and Chris […]
This paper was originally published by Melek Simsek, Berrie Meijer, Adriaan A. van Bodegraven, Nanne K.H. de Boer, and Chris […]
This article was originally published by Mahendra Saini, Nikhita Parihar, Shankar Lal Soni, and Vandana Sharma in the Asian Journal
When drug patents expire, billions of dollars in revenues can disappear overnight as competitors enter the market. Accordingly, many investors
Investing in Drug Companies? Here are 6 Vital Non-Patent Factors to Consider Read Post »
Just because a drug has received FDA approval does not mean that it is available in the marketplace. But, why
I’ll be giving a talk on Finding and Evaluating Market Entry Opportunities for a Better ROI at the upcoming 13th
Finding and Evaluating Market Entry Opportunities for a Better ROI Read Post »
The USPTO Office of the Chief Economist has releases a comprehensive set of patent litigation data files for public use.
The FDA Orange Book, or Approved Drug Products with Therapeutic Equivalence Evaluations, is the definitive source to link drugs with
Free Orange Book PDF Library from DrugPatentWatch Read Post »
This article was originally published by Syed Sauban Ghani in Eclética Química under a Creative Commons license. ABSTRACT As scientific
A comprehensive review of database resources in chemistry Read Post »
This article was originally published by Mohammed M. Alshehri and Mahmoud M. E. Mudawi in the Journal of Pharmaceutical Research